BIRC3 and cancer: Taken together, our findings have shown that cIAP2 expression is involved in HBV-induced sorafenib resistance in liver cancer, and that the inhibition of HBV replication and cIAP2 upregulation Akt pathway could partially restore cancer cell sensitivity to sorafenib.